Senhwa Biosciences, Inc. (6492.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan
Senhwa Biosciences, Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.00 m TWD | 1.07 m TWD |
| Gross profit | 477,000.00 TWD | 520,000.00 TWD |
| Operating income | -306.19 m TWD | -278.26 m TWD |
| EBIT | -291.80 m TWD | -262.68 m TWD |
| Net income | -293.75 m TWD | -264.77 m TWD |
| Diluted EPS – continuing operations | -3.24 TWD | -2.91 TWD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Senhwa Biosciences, Inc.
Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients. The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma. It also provides technical advice and consulting services. Senhwa Biosciences, Inc. is based in New Taipei City, Taiwan.
More stocks
- CSU Digital S.A. (CSUD3.SA)
- Eloro Resources Ltd. (ELO.TO)
- Daechang Forgi (015230.KS)
- Eastech Holding Limited (5225.TW)
- CapForce Inc. (CFOR)
- SIFCO INDUSTRIES INC (SIF)
- Edesa Holding SA (EDSH.BA)
- TEAM INC (TISI)
- Gyldendal ASA (GYL.OL)
- e-LITECOM CO. Ltd (041520.KQ)
- Fluent, Inc. (FLNT)
- CODEXIS, INC. (CDXS)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.